GlaxoSmithKline

Pfizer's mRNA-based influenza vaccine demonstrated 34.5% greater effectiveness against influenza A compared to standard flu vaccines in a Phase 3 trial involving over 18,000 participants aged 18-64.

SCYNEXIS has completed the transfer of BREXAFEMME's New Drug Application to GSK, allowing the pharmaceutical giant to initiate FDA discussions for the antifungal drug's relaunch.

GSK and LTZ Therapeutics announced a strategic collaboration to develop up to four potential first-in-class myeloid cell engager therapies targeting hematologic cancers and solid tumors.

GSK and the Fleming Initiative announced six new research programs using advanced AI to tackle antimicrobial resistance, with £45 million in funding over three years starting in early 2026.

SCYNEXIS announced federal funding for a five-year, $7 million annual grant supporting development of next-generation triterpenoid antifungals (fungerps) to combat resistant fungal infections.

WRN inhibitors represent a fast-emerging precision oncology segment targeting DNA repair vulnerabilities in microsatellite instability-high (MSI-H) tumors through synthetic lethality mechanisms.

Arena BioWorks, a biomedical research institute backed by $500 million from billionaire investors including Michael Dell, is abruptly shutting down less than two years after its January 2024 launch.

Neok Bio launched with $75 million in Series A funding to develop bispecific antibody-drug conjugates that simultaneously target two distinct cancer proteins.

GSK entered a worldwide exclusive license agreement with Empirico for EMP-012, a first-in-class siRNA targeting a novel therapeutic pathway for COPD treatment, with potential expansion to other inflammatory respiratory diseases.

GSK has secured exclusive worldwide rights to develop and commercialize a preclinical antibody-drug conjugate from Syndivia targeting metastatic castration-resistant prostate cancer, with potential payments up to £268 million.